Johnson & Johnson’s chief scientist said the drugmaker is recruiting over 1,000 people per day for the late-stage trial of its experimental COVID-19 vaccine and expects to have all the data needed to seek U.S. authorization by February or earlier.
“By the end of the year or around the end of the year, we should have 60,000 people in the study,” Dr. Paul Stoffels, J&J’s chief scientific officer, said in an interview ahead of this week’s Reuters Total Health conference.
“And efficacy endpoint should be there in the first few weeks or months, January or February, of the new year,” he added.
The Phase III trial of the single-dose vaccine started in late September. The company paused the trial in October because of a serious medical event in one participant and resumed after getting the green light from an independent safety panel.
For more on Reuters Events Total Health click here: https://reutersevents.com/events/healthcare/
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor